# name
Host-Derived Molecules as Novel Chagas Disease Biomarkers:
                Hypercoagulability Markers in Plasma

# metadata.dc.description.abstract[].value
The most severe clinical symptomatology of Chagas disease
                affects ~30% of those chronically infected with the Trypanosoma
                cruzi parasite. The pathogenic mechanisms that lead to
                life-threatening heart and gut tissue disruptions occur
                "silently" for a longtime in a majority of cases. As a result,
                despite there are several serological and molecular methods
                available to diagnose the infection in its acute and chronic
                stages, diagnosis is often achieved only after the onset of
                clinical symptoms in the chronic phase of the disease.
                Furthermore, although there are two drugs to treat it, the
                assessment of their performance is impractical with current
                parasite-derived diagnostics, and therapeutic efficacy cannot be
                acknowledged in a timely manner.In this chapter we present two
                procedures to measure host-derived molecules as surrogates of
                therapeutic response against chronic T. cruzi infection. Their
                outputs relate to the generation and activity of thrombin, a
                major component of the blood coagulation cascade. This is due to
                the fact that a hypercoagulability state has been described to
                occur in chronic Chagas disease patients and revert after
                treatment with benznidazole.

# metadata.dc.relation.ispartof[].value
Methods in Molecular Biology, 2019, vol. 1955

# metadata.dc.rights[].value
(c) Springer Science+Business Media, LLC., 2019

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Host-Derived Molecules as Novel Chagas Disease Biomarkers:
                Hypercoagulability Markers in Plasma